Press releases
- Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
- Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
- Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
- Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
- Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
- Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
- Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
- Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
More ▼
Key statistics
On Wednesday, Everest Medicines Ltd (6HN:MUN) closed at 2.28, 30.75% above the 52 week low of 1.74 set on Mar 16, 2022.
52-week range
Markit short selling activity
Open | 2.28 |
---|---|
High | 2.28 |
Low | 2.28 |
Bid | -- |
Offer | -- |
Previous close | 2.28 |
Average volume | 23.00 |
---|---|
Shares outstanding | 301.22m |
Free float | 301.22m |
P/E (TTM) | -- |
Market cap | 5.76bn HKD |
EPS (TTM) | -4.06 HKD |
Data delayed at least 15 minutes, as of May 25 2022 07:02 BST.
More ▼